Upper tract urothelial carcinoma (UTUC) accounts for approximately 5% of all urothelial carcinoma. There are many risk factors for UTUC, including environmental and genetic risk factors, some of which are in common with bladder cancer. The gold standard surgical management of UTUC is radical nephroureterectomy (RNU) with excision of bladder cuff, which is increasingly being performed laparoscopically or robotically with various methods used for the distal ureter. There are increasing numbers of patients being treated endoscopically, with excellent oncological outcomes in low-grade disease. The use of topical BCG and chemotherapy agents has been extrapolated from bladder cancer and may be an adjunct to endoscopic management in those patients in whom it is imperative to avoid RNU.
Introduction
Upper tract urothelial carcinoma (UTUC) is an uncommon cancer that accounts for approximately 5% of all urothelial carcinoma (UC). According to the National Cancer Institute Surveillance, Epidemiology and End Results database, the incidence of UTUC is around one in 100,000 population. 1 UTUC can arise at any point from the calyces to the distal ureter, although pelvicalyceal tumours are three times more common than those located within the ureter. UC is a disease characterised by multiplicity and multifocality. As such, in 8%-13% of new UTUC diagnoses there is concomitant bladder cancer 2 and bladder UC recurrence occurs in 15%-50% of patients with UTUC after treatment. 3 Recurrences in the contralateral upper tract are less common after UTUC treatment (in only 2%-6% patients). Synchronous bilateral UTUC are rare and occur in 1.6%-3% of patients. 4, 5 Upper tract tumours following primary bladder cancer occur in as many as 20% of patients and up to 15 years later. Therefore some authors advocate lifelong surveillance of the upper tracts. 6 In general, UTUC appear similar to bladder UC. However, as we shall describe below, there are differences in the pathological morphology, risk factors and genetics of these tumours. 2 Furthermore, anatomical and structural differences, combined with surgical technology, have necessitated alternate treatment strategies.
Risk factors

Inherited genetic factors
Epidemiological data suggest that UC primarily arises through acquired rather than inherited risk factors. These acquired exposures may interact with gene modifications to modify the carcinogen load. Examples include slow or fast variants of detoxification enzymes that prolong or reduce carcinogen exposure. 7 Furthermore, recent genome-wide association studies have identified gene polymorphisms that slightly increase disease risk when compared to the general population. 8, 9 Their functional significance is currently unknown but they appear to increase the risk of bladder UC and UTUC. 9 An exception to these acquired risks is familial UTUC that occur within the Lynch cancer syndrome. This is the commonest familiar cancer syndrome (also known as hereditary non-polyposis colon cancer (HNPCC)), and up to one-third of cancers occur outside the gastrointestinal tract. UTUC is the third commonest cancer in Lynch syndrome (accounting for 5% of tumours) after colonic (63%) and endometrial (9%) tumours. In 1317 HNPCC kindreds were found to have significantly increased incidence of cancers of the renal pelvis and ureter (22-fold increase) compared to the general population. 5 Lynch syndrome is caused by inherited mutations of one mismatch repair (MMR) gene. These encode proteins that repair DNA replication errors. Loss of MMR produces genetic instability (seen in the highly repetitive DNA microsatellite regions, termed microsatellite instability (MSI)) and carcinogenesis. 10, 11 As seen in other sites with familial cancers, a proportion (10%-15%) of sporadic UTUC also have MSI as their carcinogenic mechanism. In these tumours, MMR loss occurs mostly through epigenetic means (especially DNA promoter hypermethylation). 12 
Acquired exposures and risk factors
Acquired risk factors for UTUC may be common to the entire urinary tract or more specific to UTUC. Examples of common carcinogens include tobacco smoking and occupational exposure to aromatic amines or polycyclic aromatic hydrocarbons. Relevant occupations include workers exposed to dyes, textiles, petrochemicals, rubber and specific industries such as hairdressers, painters and aluminium manufacturers. Cigarette smoking is the commonest carcinogenic exposure for UTUC and accounts for 70% of male and 40% of female UTUC. 13 The risk is exposure related as smoking for more than 45 years' duration doubles risk extent (from 3.1-to 7.2-fold).
Risk factors specific to the upper tract include aristolochic acid nephropathy and chronic analgesic use. Aristolochic acid exposure may arise through ingestion of Chinese herbs (aristolochic acid is in the Mu Fang Ji medication) or contaminated wheat in the Balkans (Aristolichia Clematis contaminates the flour supply leading to an endemic nephropathy). 14, 15 Aristolochic acid-induced nephropathy leads to a 100-to 200-fold increase in UTUC risk compared to bladder UC. Aristolochic acid nephropathies are characterised by proximal tubular damage, renal interstitial fibrosis and slow progression to renal failure. Around half of affected patients develop urothelial cancer, and 90% of these are UTUC. Chronic consumption of the analgesic phenacetin has been recognised as a risk factor for UTUC since the 1960s. 4 Its use has been restricted or replaced and the number of UTUC cases attributed to phenacetin has diminished. There is also a high incidence of UTUC in Taiwan and an association with Blackfoot disease, 16, 17 which is caused by arsenic pollution of water. Alkylating agents such as cyclophosphamide and ifosfomide administered within chemotherapy regimens have been shown to induce UTUC via the metabolite acrolein, and chronic urinary tract infection and urolithiasis are both risk factors for UTUC. 2 
Pathological features
The vast majority of upper urinary tract tumours are UC in histological subtype. The exceptions include rare squamous cell carcinoma (<5%) in association with chronic inflammation or calculi, adenocarcinoma (<1%) and neuroendocrine carcinomas (<0.5%: including small cell, large cell and carcinoid tumours). Anatomically, most UTUC occur in the renal pelvis (3:1 ratio with the ureter). Ureteric tumours may arise in the proximal (around 5% of cases), middle (25%) or distal ureter (70%). Urothelial carcinomas are commonly multi-focal or can develop metachronously. There are two hypotheses put forward to try to explain these observations. The first is the 'field change' hypothesis, in which mutagens within the urine are in contact with the entire urothelium and therefore exert a global mutagenic effects on cells. 18 The second hypothesis is the 'clonal' hypothesis, this hypothesises that multifocal tumours are derived from a single transformed cell that spreads by intraepithelial spread or intraluminal seeding. Evidence from molecular studies reveals that most multifocal cancers are derived from single clones that spread throughout the urinary tract. 19 The staging and grading classifications for UTUC are similar to those used in bladder cancer. When compared, UTUC are more commonly invasive and high grade than bladder UC. 20 This difference may be due to disease-related factors (such as causative exposure) or structural differences (the upper urinary tract has a thinner muscular layer than the bladder). 21 The majority of UTUC are papillary in growth pattern.
Tumour stage
UTUC are staged using the tumour, node, metastasis (TNM) classification (Table 1 ). The outcomes of treatment for UTUC are strongly associated with tumour stage. For example, the five-year survival rates vary between 90% for pTa lesions and <30% for pT4 tumours. 20, 22, 23 
Tumour grade
Prior to 2004, the 1973 World Health Organisation (WHO) classification was used to grade tumours. 25, 26 The 1973 criteria defined three grades of tumour: G1, G2 and G3. The 2004 classification defined grades of tumour as papillary urothelial neoplasm of low malignant potential, low-grade and high-grade carcinomas. UTUC differ from bladder urothelial carcinoma in that tumours are more likely to be high grade; this makes ureteroscopic biopsy mandatory prior to endoscopic management (as aggressive tumours should be treated with radical nephroureterectomy (RNU) if appropriate). 21 Tumour grade from endoscopic biopsies can be used to help predict stage of disease and so help in counselling patients regarding treatment options. 27 
Diagnosis
The most common presenting symptom for UTUC is haematuria, which may be visible or non-visible. Rarer presentations include flank pain from hydronephrosis or clot colic, and abdominal loin pain from advanced disease. In advanced a mass may be palpable and there may be weight loss and pain from metastases. Many patients are asymptomatic at presentation. The diagnosis of UTUC can be hard to make, and so delays from presentation to treatment are common.
Imaging plays the key role in the diagnosis of UTUC. Intravenous urogram (IVU) was the main diagnostic test, but has been replaced by computed tomography urography (CTU). CTU includes non-contrast and excretory phases, and allows excellent imaging of the upper urinary tract and exclusion of other pathology, although the radiation dose is higher than for IVU. Radiolucent filling defects and hydronephrosis are cardinal features on CT. It is important to evaluate the contralateral kidney on CT and at times renography may be required to confirm split renal function.
The advent of smaller uretero-renoscopes (with better visualisation) has allowed direct visualisation and treatment of tumours within the ureter and renal pelvis, (Fig. 1) . Ureteroscopy allows biopsy, or washings for cytology to aid diagnosis. In a retrospective review of 512 patients it has been shown that diagnostic ureteroscopy can be performed prior to RNU without compromising oncological outcomes. 28 
Prognostic factors
Histological features appear the most predictive for outcome in UTUC. For disease progression and survival, the strongest prognostic factor appears to be tumour stage. 29, 30, 31 The five-year survival rates are between 90% and 100% for Ta and carcinoma in situ (CIS), 91.7% for T1, 72.6% for T2, and 40.5% for T3. 32 The survival rate reduces to <30% where regional lymph nodes are present and to <10% where distant metastases are present. 33 Tumour grade is also important for prognosis. High-grade tumours are associated with disease recurrence and poorer survival when compared with low-grade tumours. 30, 34 In one study of 1363 patients who underwent RNU, high-grade tumours had a much lower recurrence-free survival (88% vs 57%) and poorer survival (89% vs 63%) at five years than low-grade tumours. 34 Several other histological factors have been shown to be of importance. For example, lymphovascular invasion is an independent predictor of survival and should be mentioned in pathology reports. 29, 35, 36 Extensive tumour necrosis is also associated with biologically aggressive disease 37 and is an independent predictor of clinical outcomes. 38 Tumour architecture (sessile vs papillary) is an independent predictor of survival. 29, 39, 40 CIS is known to be associated with aggressive disease when found with urothelial carcinoma within the bladder. The presence of concomitant CIS in patients with organ-confined UTUC has been shown to be associated with disease recurrence and cancer- CT: computed tomography.
specific mortality in two large international multicentre retrospective reviews. 41, 42 Tumour multifocality has been shown to be an independent prognostic factor. 43 For example, in a study of 2492 patients who underwent open nephroureterectomy (ONU) or laparoscopic nephroureterectomy (LNU), multifocality was associated with disease progression and reduced cancer-specific survival. 44 Previous or synchronous bladder cancer has been shown to be an independent predictor for reduced recurrence-free survival as well as lower cancer-specific survival. 43, 45 There is a lack of consensus regarding whether tumour location is a prognostic factor. Several large studies have shown no difference in prognosis between ureteric and renal pelvis tumours, [46] [47] [48] and with the bladder when adjusted for case mix. In contrast, other retrospective series have reported worse outcomes for UC in the ureter when compared to those in the renal pelvis. 30, 49 Finally, older age at time of RNU has been shown to be associated with reduced cancer-specific survival. 50 The reason for this is unclear; however, age should not preclude a curative RNU in a fit elderly patient.
Treatment
Nephroureterectomy (NU) is the gold standard approach for UTUC, but may be over treatment for patients with distal ureteric or low-grade non-muscle invasive tumours, and may not be possible in patients with single upper urinary tracts (e.g. a previous contralateral UTUC). As such, there is logic in attempting nephron-sparing approaches for suitable UTUC, making treatment more analogous to that for UC within the bladder. Current data suggest that NU should always be used for high-grade or invasive UTUC and for tumours in the renal pelvis (if the contralateral urinary tract is normal and there are no strong underlying aetiologies).
RNU
RNU with excision of a bladder cuff is the gold standard treatment for UTUC. 51 This may be performed through several different open (ONU) approaches, such as a single midline incision, a thoraco-abdominal incision or a flank incision with a Gibson or Pfannelsteil incision for excision of the distal ureter and bladder cuff, or using laparoscopic (LNU) or robot-assisted laparoscopic techniques. ONU is gradually being replaced by LNU because of the lower morbidity of the latter approach. Specifically, LNU has lower blood loss, shorter hospital stays 52 and equivalent oncological outcomes to ONU at five years (as shown in a randomised controlled trial 53 ). One small study reported similar outcomes for ONU and LNU at a median of 13 years. 54 A large international multi-centre retrospective review has also shown ONU and LNU are oncologically equivalent. 55 These findings were confirmed in a recent systematic review. 56 Interestingly, a recent meta-analysis has shown LNU to be associated with lower urinary recurrence and distant metastasis but equivalent local recurrence when compared with ONU. 52 Following NU, subsequent bladder recurrence is common (up to 70%) and may be reduced by 40% with a single post-operative intravesical instillation of mitomycin-C (need to treat nine patients to prevent one bladder tumour). 57 For renal pelvic tumours, there is debate regarding the optimal management of the distal ureter. It is important to excise the entire ureter, including the ureteric orifice, and failure to do this leads to high recurrence rates. 58 The ureter must be kept in continuity to prevent tumour spillage. The gold standard method is open excision of the intramural ureter and ureteric orifice as well as a cuff of bladder; however, several alternate techniques have been described. The pluck technique was originally used with ONU; however, it is also used in conjunction with LNU. 59 Transurethral resection and stripping have all been described; however, stripping has been shown to be inferior to excision of bladder cuff. 60 A retrospective analysis of 2681 patients who underwent RNU found that there was no difference in terms of survival between different techniques; however, there was a significant increase in intravesical recurrence in patients whose distal ureter was managed endoscopically. 61 
Segmental ureteric resection
Segmental ureterectomy is usually reserved for low-grade non-invasive tumours that are too large for endoscopic treatment or patients with high-grade tumours in whom nephron sparing is imperative. Segmental ureterectomy has been shown to have comparable outcomes to RNU 62, 63 in appropriate cases and preserves nephrons.
Endoscopic management
Certain UTUC (such as low-grade non-muscle-invasive tumours) may be safely treated endoscopically, providing access can be achieved. 64 Endoscopic approaches have been facilitated by the advent of smaller ureteroscopes with better visualisation and wider working channels. Tumours difficult to access through a retrograde approach via the bladder may be approached using a percutaneous antegrade tract.
Endoscopic management is recommended for patients who have solitary (anatomically or functionally) upper tracts, those with bilateral UTUC, patients with poor baseline renal function, or those who are too co-morbid to undergo RNU, and for tumours that are low-grade, nonmuscle-invasive lesions. Candidates for endoscopic management must comply with strict post-treatment surveillance protocols. There has been some reticence regarding endoscopic management as some feel that a delay in definitive treatment may affect prognosis. One study has compared outcomes in patients who underwent NU with a group who underwent NU following ureteroscopic biopsy. This study showed at just over three years that there was no difference in disease-free survival. 65 Large tumours in the renal pelvis or lower pole tumours difficult to access retrogradely can be treated percutanously. The first documented percutaneous treatment of UTUC was by Streem and Pontes in 1986. 66 Outcomes of endoscopic management have been shown to be grade dependent. In one study grade 1 (G1) UTUC disease-specific survival at five years was 100%; however, for grade 2 (G2) disease it was 62.5% and for grade 3 (G3) it was 55.6%. Only for G1 disease were outcomes equivalent with LNU. 66 In another large series cancer-specific outcomes for G1 disease were equivalent for endoscopic management and those treated with RNU. 68 Although survival outcomes from endoscopic treatment of low-grade disease are excellent, it has been shown that there is significant upgrading of tumours when comparing biopsy grade with NU grade; in one study 96% of G1 and 40% of G2 tumours were upgraded at NU. 69 After conservative treatment, recurrences are common but recurrence is usually distal to the original tumour, and proximal recurrences are unusual.
Immunotherapy/chemotherapy following endoscopic management
Topical immunotherapy or chemotherapy can be administered either retrogradely via a ureteric catheter or antegradely via a percutaneous nephrostomy tube. 70 Agents used for adjuvant treatment of UTUC have predominantly been extrapolated from those used for bladder cancer. Several different agents have been described, including mitomycin-C, [71] [72] [73] [74] thiotepa, 75 bacillus Calmette-Guérin (BCG)/ interferon 76, 77 and BCG alone. The first BCG upper tract instillation was in 1985. 78 Retrogradely BCG has been administered using an in situ stent, and in a large study of 55 consecutive patients, BCG administered antegradely has been shown to be tolerated and associated with a high kidney preservation rate. 79 Clearly BCG has a role in those patients in whom there are imperative indications for conservative management.
Conclusions
UTUC is a rare condition which traditionally has been treated surgically with RNU and excision of bladder cuff. LNU is increasingly being performed where possible with equivalent oncological outcomes when compared with open ONU, and with increasing robotic experience more RNUs will be performed robotically. There are increasing numbers of patients undergoing endoscopic management, particularly those with low-grade disease or imperative indications, and outcomes for low-grade disease are excellent. BCG and chemotherapy agents have been utilised for the treatment of UTUC and may be an adjunct to endoscopic treatment.
